EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quality of life with nivolumab and AVD first‐line treatment of Hodgkin lymphoma in the Phase II GHSG NIVAHL trial

Christian Peter Jaworek iD, Ina Bühnen, Peter Herhaus, Julia Meissner, Karolin Trautmann-Grill iD, Teresa Halbsguth, Andrea Kerkhoff, Valdete Schaub, Michael Fuchs iD, Bastian von Tresckow iD, Peter Borchmann iD, Karolin Behringer und 1 weitere

HemaSphere · 2026-10 · 10 (10)

DOI: 10.1002/hem3.70485 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HemaSphere, online erschienen am 29.09.2026. Verfasst von Christian Peter Jaworek und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duessel…. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) University of Cologne Cologne Germany.
  • German Hodgkin Study Group (GHSG) Cologne Germany.
  • Department of Internal Medicine III TUM University Hospital, Technical University of Munich, School of Medicine and Health Munich Germany.
  • Medicine V University of Heidelberg Heidelberg Germany.
  • University Hospital Carl Gustav Carus Technische Universität Dresden Dresden Germany.
  • Department of Oncology Universitätsklinikum Frankfurt, Johann Wolfgang Goethe‑Universität Frankfurt am Main Frankfurt am Main Germany.

ORCID-Profile: Christian Peter Jaworek, Karolin Trautmann-Grill, Michael Fuchs, Bastian von Tresckow, Peter Borchmann, Paul Jan Bröckelmann

Zitieren

APA

Jaworek, C. P., Bühnen, I., Herhaus, P., Meissner, J., Trautmann-Grill, K., Halbsguth, T., Kerkhoff, A., Schaub, V., Fuchs, M., von Tresckow, B., Borchmann, P., Behringer, K., & Bröckelmann, P. J. (2026). Quality of life with nivolumab and AVD first‐line treatment of Hodgkin lymphoma in the Phase II GHSG NIVAHL trial. HemaSphere, 10(10). https://doi.org/10.1002/hem3.70485

Vancouver

Jaworek CP, Bühnen I, Herhaus P, Meissner J, Trautmann-Grill K, Halbsguth T, et al. Quality of life with nivolumab and AVD first‐line treatment of Hodgkin lymphoma in the Phase II GHSG NIVAHL trial. HemaSphere. 2026;10(10). doi:10.1002/hem3.70485

BibTeX
@article{Jaworek2026,
  author = {Jaworek, Christian Peter and Bühnen, Ina and Herhaus, Peter and Meissner, Julia and Trautmann-Grill, Karolin and Halbsguth, Teresa and Kerkhoff, Andrea and Schaub, Valdete and Fuchs, Michael and von Tresckow, Bastian and Borchmann, Peter and Behringer, Karolin and Bröckelmann, Paul Jan},
  title = {Quality of life with nivolumab and AVD first‐line treatment of Hodgkin lymphoma in the Phase II GHSG NIVAHL trial},
  journal = {HemaSphere},
  year = {2026},
  volume = {10},
  number = {10},
  doi = {10.1002/hem3.70485}
}
Kostenlos starten →